Table 2 Characteristics of included Non-randomized controlled trials

Du S (5)

2020

China

MWA

218

56.4 ± 10.3

173/45

200/18

2.9 ± 1.2

51

9

OS, RFS, C

RFA

234

57.3 ± 9.3

192/42

216/18

2.4 ± 1.0

Cillo U (6)

2014

Italy

MWA

42

64 (47–81)

35/7

NR

2.5(1.5–5.3)

24

9

OS

RFA

100

63 (34–81)

83/17

3.0(1.0–6.0)

Ghweil A (7)

2019

Egypt

MWA

25

NR

18/7

NR

≤ 5

48

8

OS, DFS, C

RFA

30

21/9

Zhang L (8)

2013

China

MWA

77

54 ± 9.5 (26–76)

67/10

77/0

≤ 5

70

8

OS, DFS, C

RFA

78

54 ± 10.5 (30–80)

64/4

78/0

Vogl TJ (9)

2015

Egypt

MWA

28

60 (45–68)

23/5

NR

3.6 (0.9–5.0)

42

8

OS, C

RFA

25

57 (40–64)

19/6

3.2 (0.8–4.5)

Potretzke TA(10)

2016

USA

MWA

99

61 (44–82)

81/18

NR

2.2 (2.0–2.3)

48

7

OS, TFS, C

RFA

55

62 (23–88)

40/15

2.4 (2.2–2.6)

Ding J (11)

2013

China

MWA

113

59.06 ± 11.68 (30–86)

85/28

75/38

2.6 ± 0.9 (0.8–5.0)

60

7

OS, DFS, C

RFA

85

58.64 ± 8.52 (40–77)

68/17

49/36

2.4 ± 0.8 (1.0–4.8)

Xu Y (12)

2017

China

MWA

301

54.2 ± 11.0

235/23

278/23

1.7 ± 0.3

102

7

OS, RFS, C

RFA

159

54.0 ± 11.0

132/27

140/19

1.7 ± 0.3

Santambrogio R (13)

2017

Italy

MWA

60

70 ± 8.3 (66–76)

43/17

60/0

2.15 ± 0.53 (1.75–2.5)

45.8

8

OS, DFS, C

RFA

94

69 ± 9(65–76)

69/25

94/0

1.92 ± 0.5 (1.5–2.2)

Hung HH (16)

2011

China

SR

229

60.1 ± 12.6

184/45

NR

2.88 ± 1.06

60

8

OS

RFA

190

67.4 ± 11.5

121/69

2.37 ± 0.92

Wong KM (17)

2013

China

SR

46

55.1 ± 12

30/16

46/0

2.1 ± 0.6

60

8

DFS, C

RFA

36

63.5 ± 13

18/18

36/0

1.9 ± 0.6

Wang JH (18)

2012

China

SR

208

NR

168/40

205/3

≤ 5

NR

8

OS, DFS

RFA

254

161/93

191/63

Imai K (19)

2013

Japan

SR

101

63.3 ± 9.7

75/26

97/4

2.14 ± 0.55

49

8

OS, DFS

RFA

82

67.6 ± 8.5

46/36

60/22

1.87 ± 0.50

Yang HJ (20)

2014

Korea

SR

52

55.7 ± 10.6

38/4

50/2

≤3

96

8

OS, C

TACE

66

59 ± 9.5

49/17

55/11

RFA

79

57.2 ± 9.2

59/20

68/11

Hocquelet A (21)

2015

France

SR

103

68(61–74)

82/21

99/4

3.5 (2.5–4)

122

8

OS, C

RFA

178

65(56–74)

148/30

145/33

2.2 (2–2.8)

Liu PH (22)

2016

China

SR

109

60 ± 13

78/31

NR

2.6 ± 1.3

96

8

OS, RFS

RFA

128

64 ± 12

84/44

2.0 ± 1.1

Guan TP (23)

2017

China

SR

92

52.48 ± 8.36

75/17

79/13

3.19 ± 0.98

60

8

OS, RFS, C

RFA

102

54.02 ± 7.66

90/12

83/19

3.10 ± 0.88

Santambrogioa R (26)

2015

Italy

SR

76

66 ± 9(61–72)

52/24

79/13

1.75 ± 0.28 (1.5–2)

197

8

OS, C

RFA

76

68 ± 8(63–73)

59/17

83/19

1.66 ± 0.36 (1.5–2)

Oh JH (27)

2020

Korea

SR

48

54.5(50.2–61.7)

37/11

NR

≤ 3

84

8

OS, RFS, C

TACE

141

62.0(54.5–67)

112/29

RFA

87

59(51.0–68.0)

72/15

Hsiao CY (28)

2020

China

SR

156

58.8 ± 1.7(27–82)

95/61

NR

1.46 ± 0.31 (0.5–1.9)

65.1

7

OS, RFS

RFA

231

62.2  ±  12.3(31–84)

141/90

1.58 ± 0.24 (0.8–1.9)

Liang B (29)

2018

China

SR

64

48.8(26–74)

54/10

58/6

3.1 (1.5–5.0)

66

7

OS, RFS, C

RFA

58

51.4(30–85)

48/10

53/5

2.9 (1.2–5.0)

Di Sandro S (31)

2019

Italy

MIS

51

68(62–76)

33/17

NR

2.5 (2.0–3.0)

60

8

OS, RFS, C

SR

341

66(59–73)

68/23

3.5 (2.5–5.6)

RFA

143

65(57–75)

66/25

2.0 (1.6–2.5)

Santambrogio R (32)

2018

Italy

MIS

59

68 ± 9

42/17

59/0

2.09 ± 0.67 (1.5–2.6)

54

8

OS, C

RFA

205

69 ± 9

152/53

205/0

1.91 ± 0.58 (1.5–2.2)

Casaccia M (33)

2017

Italy

MIS

24

63.58 ± 9.55

16/8

22/2

3.3 ± 1.4

72

8

OS, DFS

RFA

22

60.82 ± 7.25

18/4

12/10

2.6 ± 1.3

Song J (34)

2015

China

MIS

78

48(44–57)

70/8

78/0

≤ 4

96

9

OS, RFS, C

RFA

78

48(43–58)

70/8

78/0

Vitali GC (35)

2015

Switerland

MIS

45

61.4(31–84)

30/15

40/5

2.3 (1–3)

129

8

OS, C

RFA

60

67.3(47–83)

52/8

15/15

2.1 (2.1–3)

Ogiso S (36)

2020

Japan

MIS

85

69(46–88)

62/23

73/12

2.1 (0.8–3)

153

8

OS, RFS, C

RFA

136

73(47–87)

98/38

110/26

1.6 (0.5–3)

Chong CC (37)

2020

China

MIS

59

57.7 ± 10.5

46/13

59/0

2.0 (1.6–2.8)

72.3

8

OS, DFS, C

RFA

155

62.1 ± 9.8

120/35

143/2

2.0 (1.6–2.7)

Wahl DR (38)

2016

USA

SBRT

63

62(35–85)

54/9

43/20

≤ 5

112.8

8

OS, C

RFA

161

60(31–81)

117/44

80/81

Kim N (39)

2019

Korea

SBRT

105

63.0 (35.0–86.0)

86/19

97/8

2.4 (0.7–5.5)

37.3

9

PFS, C

RFA

668

64.0 (26.0–86.0)

523/145

599/69

1.6 (0.5–4.6)

Sun J (40)

2020

China

SBRT

122

54.31 ± 9.35

90/32

111/11

2.62 ± 1.09

117

8

OS, RFS, C

SR

195

52.20 ± 9.54

156/39

193/2

2.81 ± 1.13

Nakano R (41)

2018

Japan

SBRT

27

72.6 ± 9.1

15/12

238/16

18.3 ± 1.4

60

8

OS, DFS, C

SR

254

68.1 ± 10.2

183/71

23/4

19.4 ± 6.0

Martin AN (42)

2019

USA

TACE

27

66.6 ± 8.7

19/8

NR

18 (13–27)

62.4

8

OS

RFA

27

67.1 ± 11

15/12

20 (14–23)

Xu J (44)

2018

USA

CRA

94

65.9±10.1

73/21

NR

28 (21–38)

120

7

OS

RFA

3145

62.5±9.7

2353/792

27 (20–36)

Hu J (45)

2019

China

CRA

56

54.9±11.3(28–75)

42/14

46/10

36.5 ± 8.5 (16–57)

46.2

8

OS, RFS, C

WMA

64

55.2±7.2(32–73)

46/18

50/14

32.5±7.2 (16–42)